Complement-targeted therapeutics: Are we there yet, or just getting started?

Area of Science:

• Immunology
• Pharmacology
• Drug Discovery

Background:

• The complement system is a crucial immune mediator implicated in various diseases.
• Targeting the complement system for therapeutic purposes was historically challenging.
• Recent advancements have demonstrated the clinical and commercial feasibility of complement-targeted therapies.

Purpose of the Study:

• To review the historical milestones in complement drug discovery and development.
• To survey currently approved complement-specific therapeutics and their indications.
• To provide insights into future advancements in the field.

Main Methods:

• Literature review of complement drug discovery and development.
• Analysis of approved complement-specific therapeutics and clinical indications.
• Exploration of emerging trends and future prospects in complement therapy.

Main Results:

• The field of complement-targeted therapy has expanded rapidly over the past two decades.
• A dozen distinct complement-specific therapeutics are now available, treating eight disorders.
• Numerous clinical trials and off-label uses further demonstrate the growing impact of these therapies.

Conclusions:

• Complement-targeted therapies have evolved from challenging concepts to mainstream clinical options.
• The field continues to advance, with ongoing research and development promising further breakthroughs.
• Future advancements are expected to expand treatment modalities and address a broader range of conditions.